Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence

References

• CAPRIE Steering Committee. Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Sacco RD, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359(12):1238-51
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherotrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367(9):817-25
   Google Scholar
• Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49(19):1982-8
   PubMed Web of Science ®Google Scholar
• Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7
   PubMed Web of Science ®Google Scholar
• The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78
   PubMed Web of Science ®Google Scholar
• European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507
   PubMed Web of Science ®Google Scholar
• Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76
   PubMed Web of Science ®Google Scholar
• Coull A, Lovett JK, Rothwell PM; on behalf of the Oxford Vascular Study. Early risk of stroke after a TIA or minor stroke in a population-based incidence study. BMJ 2004;328:326-8
   PubMed Web of Science ®Google Scholar
• Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007;6:1063-72
   PubMed Web of Science ®Google Scholar
• Thebault JJ, Kieffer G, Lowe GD, et al. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999;25(Suppl 2):9-14
   PubMedGoogle Scholar
• Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000;20:2316-21
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention : a randomized controlled trial. JAMA 2002;288(19):2411-20
   PubMed Web of Science ®Google Scholar
• Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. J Am Coll Cardiol 2009;54:1438-46
   PubMed Web of Science ®Google Scholar
• Markus HS, Droste DW, Kaps M. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection. Circulation 2005;111:2233-40
   PubMed Web of Science ®Google Scholar
• Wong KSL, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study) : a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489-97
   PubMed Web of Science ®Google Scholar
• Kennedy J, Hill MD, Ryckborst KJ, for the FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized, controlled pilot trial. Lancet Neurol 2007;6:961-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369(1):11-19
   PubMed Web of Science ®Google Scholar
• Savi P, Herbert JM. Clopidogrel and ticlopidine : P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31:174-83
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang I, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases and clopidogrel is transesterificated in the presence of ethyl acohol. J Pharmacol Exp Ther 2006;319(3):1467-76
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thyenopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin. Pharmacol 2010;50(2):126-42
   PubMed Web of Science ®Google Scholar
• Pereillo J-M, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30(11):1288-95
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos 2010;38(1):92-9
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84(5):891-6
   PubMed Web of Science ®Google Scholar
• Hurst NL, Nooney VB, Raman B, et al. Clopidogrel “resistance”: pre- vs post-receptor determinants. Vasc Pharmacol 2013;59:152-61
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
   PubMed Web of Science ®Google Scholar
• Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. A systematic review and meta-analysis. JAMA 2011;306(24):2704-14
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94(3):317-23
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P459 C3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26(8):1895-900
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17(1):110-16
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011;32:13-1605-13
   PubMed Web of Science ®Google Scholar
• Gong IY, Crown N, Suen CN, et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J 2012;33:2856-64
   PubMed Web of Science ®Google Scholar
• Frelinger Al, Lee Rd, Mulford Dj, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol 2012;59(14):1304-11
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
   PubMed Web of Science ®Google Scholar
• Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009;10:1017-24
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-63
   PubMed Web of Science ®Google Scholar
• Ojeifo O, Wiviott SD, Antman EN, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv 2013;6(12). 1275-81
   PubMed Web of Science ®Google Scholar
• Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013;62:505-12
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel in 544 individuals. J Am Coll Cardiol 2005;45:246-51
   PubMed Web of Science ®Google Scholar
• Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999;25(Suppl 2):3-8
   PubMedGoogle Scholar
• Müller I, Seyfarth M, Silja R, et al. Effects of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-3
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of clopidogrel high loading doses in patients with non-ST-segment elevation acute coronary syndromes : the ALBION (Assesment of the Best Loading Dose of Clopidogrel to Blunt Platelet activation, Inflammation, and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48(5):931-8
   PubMed Web of Science ®Google Scholar
• Von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Circulation 2005;112:2946-50
   PubMed Web of Science ®Google Scholar
• Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose. Circulation 2008;118:1225-33
   PubMed Web of Science ®Google Scholar
• Kastrati A, von Beckerath N, Joost A, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004;110:1916-19
   PubMed Web of Science ®Google Scholar
• Hamm W, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. Eur Heart J 2011;32:299-3054
   Web of Science ®Google Scholar
• The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. ESC guidelines for the management of acute myocardial infarction in patients with ST-segment elevation. Eur. Heart J 2012;33:2569-619
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates R, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guidelines for percutaneous coronary interventions: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society of Cardiovascular Angiography and Interventions. Circulation 2011;124:e574-651
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:4-e362-425
   Web of Science ®Google Scholar
• Von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814-19
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Circulation 2007;115:708-16
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. The GRAVITAS randomized trial. JAMA 2011;305(11):1097-105
   PubMed Web of Science ®Google Scholar
• Mega JL, Hochholzer W, Frelinger AL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306(20):2221-8
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382:614-23
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62(24):2261-73
   PubMed Web of Science ®Google Scholar
• Qureshi Z, Hobson AR. Clopidogrel “resistance”: where are we now. Cardiovasc Ther 2013;31:3-11
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb. Haemost 2009;101:333-9
   PubMed Web of Science ®Google Scholar
• Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary interventions. Eur Heart J 2014;35:209-15
   PubMed Web of Science ®Google Scholar
• Bonello L, Mancini J, Pansieri M, et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012;10:10-1999-2005
   Web of Science ®Google Scholar
• Bonello L, Laine M, Baumstarck K, et al. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. Int J Cardiol 2013;168(4):4244-8
   PubMed Web of Science ®Google Scholar
• Frelinger AL, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existing variability in platelet function. J Am Coll Cardiol 2013;61:872-9
   PubMed Web of Science ®Google Scholar
• Kirtane A, Rinaldi M, Parise H, et al. Impact of point-of-care platelet function testing among patients with and without acute coronary syndromes undergoing PCI with drug-eluting stents: an ADAPT-DES substudy. J Am Coll Cardiol 2012;59:E291
   Web of Science ®Google Scholar
• Gurbel P, Erlinge D, Ohman E, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization : the TRILOGY ACS platelet function substudy. JAMA 2012;308:1785-94
   PubMed Web of Science ®Google Scholar
• Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9
   PubMed Web of Science ®Google Scholar
• Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after TIA. Lancet 2007;369:283-92
   PubMed Web of Science ®Google Scholar
• The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82
   PubMed Web of Science ®Google Scholar
• Claiborne Johnston S, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial : rationale and design. Int J Stroke 2013;8:479-83
   PubMed Web of Science ®Google Scholar
• Triple antiplatelets for reducing dependency after ischemic stroke (TARDIS). Available from: www.clinicaltrials.gov/ct2/show/NCT01661322?term=TARDIS&rank=1 [Last accessed 17 March 2014]
   Google Scholar
• Wong KSL, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. Circulation 2013;128:1656-66
   PubMed Web of Science ®Google Scholar
• Censori B, Partziguian T, Casto L, et al. Doppler microembolic signals predict ischemic recurrences in symptomatic carotid stenosis. Acta Neurol. Scand 2000;101(5):327-31
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenosis and occlusions in China. Stroke 2014;45:663-9
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Kerasnoudis A, Krogias C, et al. Clopidogrel load for emboli reduction in patients with symptomatic carotid stenosis undergoing urgent carotid endarterectomy. Stroke 2012;43:1957-60
   PubMed Web of Science ®Google Scholar
• Patti G, Tomai F, Melfi R, et al. Strategies of clopidogrel load and atorvastatin reload to prevent cerebral ischemic events in patients undergoing protected carotid stenting. J Am Coll Cardiol 2013;61:1379-87
   PubMed Web of Science ®Google Scholar
• Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62(4):569-73
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Alberts MJ, Hanley DF. Prasugrel in the poststroke cohort of the TRITON trial : the clear and present danger. Cerebrovasc. Dis 2008;26:93-4
   PubMed Web of Science ®Google Scholar
• James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012;125:2914-29121
   PubMed Web of Science ®Google Scholar